Epigenetics company VolitionRx published a preprint describing 'Capture‑Seq,' a ChIP‑Seq adaptation isolating ultrashort cell‑free DNA fragments bound to the transcription factor CTCF, producing a large signal amplification for cancer detection in plasma. The team reported a 180‑fold enrichment of CTCF‑associated cfDNA after immunocapture and claims the method removes roughly 99% of background nucleosomal DNA. VolitionRx seeks partners to validate and license the technique for clinical development; the company pitched Capture‑Seq as a new biomarker class for liquid biopsies that could complement mutation‑based ctDNA assays. CTCF occupancy differences between cancer and control plasma samples underpin the proposed diagnostic signal.